Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 487 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact487 DOIs

Add abstracts to 442 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact442 DOIs

Deposit reference lists for 122 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact122 DOIs

DOIs for this ISSN

Showing the top 5 of 1522 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	The future of Japanese encephalitis vaccination: expert reco… (10.1038/s41541-021-00338-z)	Abstract ORCID	95.42	80
2	Current status of monkeypox vaccines (10.1038/s41541-022-00527-4)	Abstract ORCID	92.87	71
3	Advances and prospects of respiratory mucosal vaccines: mech… (10.1038/s41541-025-01280-0)	Abstract ORCID	72.36	27
4	Impact of inactivated vaccine on transmission and evolution… (10.1038/s41541-025-01115-y)	Abstract ORCID	67.12	21
5	Exploring Clec9a in dendritic cell-based tumor immunotherapy… (10.1038/s41541-025-01084-2)	Abstract ORCID	62.76	17
6	Vaccinology in the twenty-first century (10.1038/npjvaccines.2016.9)	Abstract ORCID	60.21	15
7	NHBA antibodies elicited by 4CMenB vaccination are key for s… (10.1038/s41541-024-01018-4)	Abstract ORCID	60.21	15
8	Cellular and molecular synergy in AS01-adjuvanted vaccines r… (10.1038/s41541-017-0027-3)	ORCID	59.68	243
9	Unmodified mRNA in LNPs constitutes a competitive technology… (10.1038/s41541-017-0032-6)	ORCID	59.64	242
10	A KIF20A-based thermosensitive hydrogel vaccine effectively… (10.1038/s41541-024-01060-2)	Abstract ORCID	58.80	14
11	The outbreak of SARS-CoV-2 pneumonia calls for viral vaccine… (10.1038/s41541-020-0170-0)	Abstract	56.62	183
12	Immunogenicity and protective efficacy of an intranasal neur… (10.1038/s41541-025-01209-7)	Abstract ORCID	55.70	12
13	A novel nanoparticle vaccine displaying multistage tuberculo… (10.1038/s41541-025-01216-8)	Abstract ORCID	55.70	12
14	The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and q… (10.1038/s41541-018-0057-5)	ORCID	54.97	157
15	Zika vaccine candidates progress through nonclinical develop… (10.1038/npjvaccines.2016.23)	Abstract ORCID	53.96	11
16	Obesity does not influence SARS-CoV-2 humoral vaccine immuno… (10.1038/s41541-024-01022-8)	Abstract ORCID	53.96	11
17	Emulsion adjuvant-induced uric acid release modulates optima… (10.1038/s41541-025-01130-z)	Abstract ORCID	53.96	11
18	An RBD-Fc mucosal vaccine provides variant-proof protection… (10.1038/s41541-025-01155-4)	Abstract ORCID	53.96	11
19	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high… (10.1038/s41541-021-00311-w)	ORCID	53.50	137
20	Access to and equitable distribution of COVID-19 vaccine in… (10.1038/s41541-021-00323-6)	Abstract	52.16	121
21	The adjuvant effect of manganese on tuberculosis subunit vac… (10.1038/s41541-024-01049-x)	Abstract ORCID	52.07	10
22	Global vaccine confidence trends among adults above and belo… (10.1038/s41541-025-01217-7)	Abstract ORCID	52.07	10
23	Matrix-M adjuvant triggers inflammasome activation and enabl… (10.1038/s41541-025-01243-5)	Abstract ORCID	52.07	10
24	Trehalose-loaded LNPs enhance mRNA stability and bridge in v… (10.1038/s41541-025-01253-3)	Abstract ORCID	52.07	10
25	Escherichia coli-derived virus-like particles in vaccine dev… (10.1038/s41541-017-0006-8)	ORCID	51.61	115
26	Mucosal vaccines for SARS-CoV-2: scientific gaps and opportu… (10.1038/s41541-023-00654-6)	Abstract	51.03	109
27	Cell culture-derived influenza vaccines in the severe 2017–2… (10.1038/s41541-018-0079-z)	ORCID	50.53	104
28	Optimizing rabies mRNA vaccine efficacy via RABV-G structura… (10.1038/s41541-025-01098-w)	Abstract ORCID	50.00	9
29	Comparison of rArt v 1-based sublingual and subcutaneous imm… (10.1038/s41541-025-01112-1)	Abstract ORCID	50.00	9
30	Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine in… (10.1038/s41541-025-01201-1)	Abstract ORCID	50.00	9
31	A self-amplifying mRNA vaccine expressing PRV gD induces rob… (10.1038/s41541-025-01251-5)	Abstract ORCID	50.00	9
32	Establishing long-lasting vaccine immunity: insights from mR… (10.1038/s41541-025-01302-x)	Abstract ORCID	50.00	9
33	COVID-19 vaccines: breaking record times to first-in-human t… (10.1038/s41541-020-0188-3)	Abstract	48.98	90
34	A chimeric haemagglutinin-based influenza split virion vacci… (10.1038/npjvaccines.2016.15)	ORCID	47.71	80
35	Current status of Zika vaccine development: Zika vaccines ad… (10.1038/s41541-018-0061-9)	ORCID	47.71	80
36	Impact of genotypic variability of measles virus T-cell epit… (10.1038/s41541-025-01088-y)	Abstract ORCID	47.71	8
37	IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell d… (10.1038/s41541-025-01213-x)	Abstract ORCID	47.71	8
38	Modulation of oral vaccine efficacy by the gut microbiota (10.1038/s41541-025-01240-8)	Abstract ORCID	47.71	8
39	Loop structure in poly(A) tail of mRNA vaccine enhances anti… (10.1038/s41541-025-01287-7)	Abstract ORCID	47.71	8
40	Neutrophil swarming and extracellular trap formation play a… (10.1038/s41541-016-0001-5)	ORCID	46.88	74
41	AS03-adjuvanted H5N1 vaccine promotes antibody diversity and… (10.1038/s41541-018-0076-2)	ORCID	46.73	73
42	Plague vaccine: recent progress and prospects (10.1038/s41541-019-0105-9)	ORCID	46.58	72
43	Humoral and cell-mediated immune responses to H5N1 plant-mad… (10.1038/s41541-017-0043-3)	ORCID	46.28	70
44	Malaria vaccine candidate based on Duffy-binding protein eli… (10.1038/s41541-018-0083-3)	ORCID	45.81	67
45	Advances in malaria vaccine development: report from the 201… (10.1038/s41541-017-0035-3)	ORCID	45.49	65
46	From therapeutic antibodies to immune complex vaccines (10.1038/s41541-018-0095-z)	ORCID	45.49	65
47	Microfluidic cell squeeze-based vaccine comes into clinical… (10.1038/s41541-023-00641-x)	Abstract ORCID	45.15	7
48	Rational selection of TbpB variants yields a bivalent vaccin… (10.1038/s41541-024-01054-0)	Abstract ORCID	45.15	7
49	Rapid development of attenuated IBV vaccine candidates throu… (10.1038/s41541-025-01114-z)	Abstract ORCID	45.15	7
50	Cellular immune signatures and differences of four porcine c… (10.1038/s41541-025-01138-5)	Abstract ORCID	45.15	7